APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug

Compare research editions
View pricing & licenses

Selected research

Market Structure

Global Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032

Report ID 174045330319 December 2025188 pages

Choose your research edition.

Industry ResearchVaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Industry Research Report 2026113 pages · $2,950 USDIndustry Growth & TrendsGlobal Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Industry Growth and Trends Forecast to 203288 pages · $3,450 USDMarket StructureGlobal Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032188 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Market Outlook and Growth Opportunities 2026197 pages · $4,250 USDMarket Analysis & ForecastGlobal Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Market Analysis and Forecast 2026-2032194 pages · $4,950 USD

Market perspective

The global Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a CAGR of xx% over 2026-2032.

The US & Canada market for Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The China market for Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug include Novartis AG, Pfizer Inc, AstraZeneca Plc, Seattle Genetics Inc, NuvOx Pharma LLC, Modus Therapeutics Holding AB, Gilead Sciences Inc and Bristol-Myers Squibb Company, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

Report Includes

This report provides an overview of the global Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug market and its size, analyzing global market trends based on historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug and revenue in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering revenue and growth rates—for 2021-2032, and evaluates and forecasts the Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug market size, projected growth trends, production technologies, key applications, and end-use industries.

Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Segment by Company

Novartis AG

Pfizer Inc

AstraZeneca Plc

Seattle Genetics Inc

NuvOx Pharma LLC

Modus Therapeutics Holding AB

Gilead Sciences Inc

Bristol-Myers Squibb Company

Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Segment by Type

SGD-2083

Crizanlizumab

PF-04447943

NVX-508

Others

Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Segment by Application

Clinic

Hospital

Others

Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. Revenue of Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug industry.

Chapter 3: Detailed analysis of Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug companies' competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drugrevenue, gross margin, and recent development, etc.

Chapter 7: North America (US & Canada) by type, by application and by country, revenue for each segment.

Chapter 8: Europe by type, by application and by country, revenue for each segment.

Chapter 9: China by type, and by application, revenue for each segment.

Chapter 10: Asia (excluding China) by type, by application and by region, revenue for each segment.

Chapter 11: South America, Middle East & Africa by type, by application and by country, revenue for each segment.

Chapter 12: Concluding Insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Market Size Growth Rate by Type (US$ Million): 2021 VS 2025 VS 2032 Table 2. Key Players of SGD-2083 Table 3. Key Players of Crizanlizumab Table 4. Key Players of PF-04447943 Table 3. Key Players of NVX-508 Table 4. Key Players of Others Table 5. Global Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Market Size Growth Rate by Application (US$ Million): 2021 VS 2025 VS 2032 Table 6. Key Players of Clinic Table 7. Key Players of Hospital Table 8. Key Players of Others Table 9. Global Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Market Size Growth Rate (CAGR) by Region (US$ Million): 2021 VS 2025 VS 2032 Table 10. Global Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Market Size by Region (2021-2026) & (US$ Million) Table 11. Global Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Market Share by Region (2021-2026) Table 12. Global Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Market Size by Region (2027-2032) & (US$ Million) Table 13. Global Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Market Share by Region (2027-2032) Table 14. Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Industry Trends Table 15. Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Industry Drivers Table 16. Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Industry Opportunities and Challenges Table 17. Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Industry Restraints Table 18. Global Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Revenue by Company (US$ Million) & (2021-2026) Table 19. Global Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Revenue Market Share by Company (2021-2026) Table 20. Global Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Players Revenue Ranking, 2024 VS 2025 VS 2026 Table 21. Global Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Key Company Head Office and Area Served Table 22. Global Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Company, Product Type & Application Table 23. Global Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Company Establishment Date Table 24. Global Company Market Concentration Ratio (CR5 and HHI) Table 25. Global Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2025) Table 26. Global Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Market Size by Type 2021 VS 2025 VS 2032 (US$ Million) Table 27. Global Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Market Size by Type (2021-2026) & (US$ Million) Table 28. Global Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Market Size by Type (2027-2032) & (US$ Million) Table 29. Global Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Revenue Market Share by Type (2021-2026) Table 30. Global Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Revenue Market Share by Type (2027-2032) Table 31. Global Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Market Size by Application 2021 VS 2025 VS 2032 (US$ Million) Table 32. Global Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Market Size by Application (2021-2026) & (US$ Million) Table 33. Global Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Market Size by Application (2027-2032) & (US$ Million) Table 34. Global Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Revenue Market Share by Application (2021-2026) Table 35. Global Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Revenue Market Share by Application (2027-2032) Table 36. Novartis AG Company Information Table 37. Novartis AG Business Overview Table 38. Novartis AG Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Revenue and Gross Margin (US$ Million) & (2021-2026) Table 39. Novartis AG Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Product Portfolio Table 40. Novartis AG Recent Development Table 41. Pfizer Inc Company Information Table 42. Pfizer Inc Business Overview Table 43. Pfizer Inc Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Revenue and Gross Margin (US$ Million) & (2021-2026) Table 44. Pfizer Inc Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Product Portfolio Table 45. Pfizer Inc Recent Development Table 46. AstraZeneca Plc Company Information Table 47. AstraZeneca Plc Business Overview Table 48. AstraZeneca Plc Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Revenue and Gross Margin (US$ Million) & (2021-2026) Table 49. AstraZeneca Plc Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Product Portfolio Table 50. AstraZeneca Plc Recent Development Table 51. Seattle Genetics Inc Company Information Table 52. Seattle Genetics Inc Business Overview Table 53. Seattle Genetics Inc Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Revenue and Gross Margin (US$ Million) & (2021-2026) Table 54. Seattle Genetics Inc Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Product Portfolio Table 55. Seattle Genetics Inc Recent Development Table 56. NuvOx Pharma LLC Company Information Table 57. NuvOx Pharma LLC Business Overview Table 58. NuvOx Pharma LLC Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Revenue and Gross Margin (US$ Million) & (2021-2026) Table 59. NuvOx Pharma LLC Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Product Portfolio Table 60. NuvOx Pharma LLC Recent Development Table 61. Modus Therapeutics Holding AB Company Information Table 62. Modus Therapeutics Holding AB Business Overview Table 63. Modus Therapeutics Holding AB Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Revenue and Gross Margin (US$ Million) & (2021-2026) Table 64. Modus Therapeutics Holding AB Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Product Portfolio Table 65. Modus Therapeutics Holding AB Recent Development Table 66. Gilead Sciences Inc Company Information Table 67. Gilead Sciences Inc Business Overview Table 68. Gilead Sciences Inc Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Revenue and Gross Margin (US$ Million) & (2021-2026) Table 69. Gilead Sciences Inc Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Product Portfolio Table 70. Gilead Sciences Inc Recent Development Table 71. Bristol-Myers Squibb Company Company Information Table 72. Bristol-Myers Squibb Company Business Overview Table 73. Bristol-Myers Squibb Company Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Revenue and Gross Margin (US$ Million) & (2021-2026) Table 74. Bristol-Myers Squibb Company Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Product Portfolio Table 75. Bristol-Myers Squibb Company Recent Development Table 76. North America Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Market Size by Type (2021-2026) & (US$ Million) Table 77. North America Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Market Size by Type (2027-2032) & (US$ Million) Table 78. North America Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Market Size by Application (2021-2026) & (US$ Million) Table 79. North America Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Market Size by Application (2027-2032) & (US$ Million) Table 80. North America Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Market Size by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 81. North America Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Market Size by Country (2021-2026) Table 82. North America Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Market Size by Country (2027-2032) Table 83. Europe Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Market Size by Type (2021-2026) & (US$ Million) Table 84. Europe Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Market Size by Type (2027-2032) & (US$ Million) Table 85. Europe Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Market Size by Application (2021-2026) & (US$ Million) Table 86. Europe Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Market Size by Application (2027-2032) & (US$ Million) Table 87. Europe Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Market Size by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 88. Europe Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Market Size by Country (2021-2026) Table 89. Europe Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Market Size by Country (2027-2032) Table 90. China Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Market Size by Type (2021-2026) & (US$ Million) Table 91. China Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Market Size by Type (2027-2032) & (US$ Million) Table 92. China Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Market Size by Application (2021-2026) & (US$ Million) Table 93. China Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Market Size by Application (2027-2032) & (US$ Million) Table 94. Asia Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Market Size by Type (2021-2026) & (US$ Million) Table 95. Asia Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Market Size by Type (2027-2032) & (US$ Million) Table 96. Asia Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Market Size by Application (2021-2026) & (US$ Million) Table 97. Asia Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Market Size by Application (2027-2032) & (US$ Million) Table 98. Asia Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Market Size by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 99. Asia Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Market Size by Country (2021-2026) Table 100. Asia Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Market Size by Country (2027-2032) Table 101. South America, Middle East & Africa Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Market Size by Type (2021-2026) & (US$ Million) Table 102. South America, Middle East & Africa Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Market Size by Type (2027-2032) & (US$ Million) Table 103. South America, Middle East & Africa Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Market Size by Application (2021-2026) & (US$ Million) Table 104. South America, Middle East & Africa Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Market Size by Application (2027-2032) & (US$ Million) Table 105. South America, Middle East & Africa Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Market Size by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 106. South America, Middle East & Africa Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Market Size by Country (2021-2026) Table 107. South America, Middle East & Africa Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Market Size by Country (2027-2032) Table 108. Research Programs/Design for This Report Table 109. Authors List of This Report Table 110. Secondary Sources Table 111. Primary Sources List of Figures Figure 1. Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Product Image Figure 2. Global Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Market Size Growth Rate by Type, 2021 VS 2025 VS 2032 (US$ Million) Figure 3. Global Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Market Share by Type: 2025 VS 2032 Figure 4. SGD-2083 Image Figure 5. Crizanlizumab Image Figure 6. PF-04447943 Image Figure 7. NVX-508 Image Figure 8. Others Image Figure 9. Global Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Market Size Growth Rate by Application, 2021 VS 2025 VS 2032 (US$ Million) Figure 10. Global Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Market Share by Application: 2025 VS 2032 Figure 11. Clinic Image Figure 12. Hospital Image Figure 13. Others Image Figure 14. Global Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 15. Global Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Market Size (2021-2032) & (US$ Million) Figure 16. Global Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Market Share by Region: 2025 VS 2032 Figure 17. Years Considered Figure 18. Global Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Market Share by Players in 2025 Figure 19. Global Top 5 and 10 Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Players Market Share by Revenue in 2025 Figure 20. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 21. Global Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Market Size by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 22. Global Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Revenue Market Share by Type (2021-2032) Figure 23. Global Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Market Size by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 24. Global Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Revenue Market Share by Application (2021-2032) Figure 25. North America Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Market Size (2021-2032) & (US$ Million) Figure 26. North America Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Market Share by Type (2021-2032) Figure 27. North America Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Market Share by Application (2021-2032) Figure 28. North America Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Market Share by Country (2021-2032) Figure 29. United States Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Market Size (2021-2032) & (US$ Million) Figure 30. Canada Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Market Size (2021-2032) & (US$ Million) Figure 31. Mexico Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Market Size (2021-2032) & (US$ Million) Figure 32. Europe Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Market Size (2021-2032) & (US$ Million) Figure 33. Europe Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Market Share by Type (2021-2032) Figure 34. Europe Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Market Share by Application (2021-2032) Figure 35. Europe Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Market Share by Country (2021-2032) Figure 36. Germany Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Market Size (2021-2032) & (US$ Million) Figure 37. France Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Market Size (2021-2032) & (US$ Million) Figure 38. U.K. Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Market Size (2021-2032) & (US$ Million) Figure 39. Italy Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Market Size (2021-2032) & (US$ Million) Figure 40. Russia Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Market Size (2021-2032) & (US$ Million) Figure 41. Nordic Countries Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Market Size (2021-2032) & (US$ Million) Figure 42. China Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Market Size (2021-2032) & (US$ Million) Figure 43. China Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Market Share by Type (2021-2032) Figure 44. China Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Market Share by Application (2021-2032) Figure 45. Asia Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Market Size (2021-2032) & (US$ Million) Figure 46. Asia Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Market Share by Type (2021-2032) Figure 47. Asia Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Market Share by Application (2021-2032) Figure 48. Asia Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Market Share by Country (2021-2032) Figure 49. Japan Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Market Size (2021-2032) & (US$ Million) Figure 50. South Korea Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Market Size (2021-2032) & (US$ Million) Figure 51. Taiwan Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Market Size (2021-2032) & (US$ Million) Figure 52. Southeast Asia Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Market Size (2021-2032) & (US$ Million) Figure 53. India Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Market Size (2021-2032) & (US$ Million) Figure 54. Australia Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Market Size (2021-2032) & (US$ Million) Figure 55. South America, Middle East & Africa Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Market Size (2021-2032) & (US$ Million) Figure 56. South America, Middle East & Africa Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Market Share by Type (2021-2032) Figure 57. South America, Middle East & Africa Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Market Share by Application (2021-2032) Figure 58. South America, Middle East & Africa Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Market Share by Country (2021-2032) Figure 59. Brazil Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Market Size (2021-2032) & (US$ Million) Figure 60. South Africa Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Market Size (2021-2032) & (US$ Million) Figure 61. Saudi Arabia Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Market Size (2021-2032) & (US$ Million) Figure 62. Turkey Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Market Size (2021-2032) & (US$ Million) Figure 63. Argentina Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Market Size (2021-2032) & (US$ Million) Figure 64. UAE Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Market Size (2021-2032) & (US$ Million) Figure 65. Egypt Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Market Size (2021-2032) & (US$ Million) Figure 66. Chile Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Market Size (2021-2032) & (US$ Million) Figure 67. Research Process Figure 68. Key Executives Interviewed

Scope & coverage.

Types
  • SGD-2083
  • Crizanlizumab
  • PF-04447943
  • NVX-508
  • Others
Applications
  • Clinic
  • Hospital
  • Others
Companies covered
  • Novartis AG
  • Pfizer Inc
  • AstraZeneca Plc
  • Seattle Genetics Inc
  • NuvOx Pharma LLC
  • Modus Therapeutics Holding AB
  • Gilead Sciences Inc
  • Bristol-Myers Squibb Company

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Market Analysis by Type
  3. 1.2.1 Global Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Market Size Growth Rate by Type: 2021 VS 2025 VS 2032
  4. 1.2.2 SGD-2083
  5. 1.2.3 Crizanlizumab
  6. 1.2.4 PF-04447943
  7. 1.2.5 NVX-508
  8. 1.2.6 Others
  9. 1.3 Market Analysis by Application
  10. 1.3.1 Global Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Market Size Growth Rate by Application: 2021 VS 2025 VS 2032
  11. 1.3.2 Clinic
  12. 1.3.3 Hospital
  13. 1.3.4 Others
  14. 1.4 Global Market Growth Prospects
  15. 1.5 Global Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Growth Trends by Region
  16. 1.5.1 Global Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Market Size by Region: 2021 VS 2025 VS 2032
  17. 1.5.2 Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Market Size by Region (2021-2026)
  18. 1.5.3 Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Market Size by Region (2027-2032)
  19. 1.6 Assumptions and Limitations
  20. 1.7 Study Goals and Objectives
  21. 1.8 Years Considered
2 Global Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Market Dynamics
  1. 2.1 Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Industry Trends
  2. 2.2 Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Industry Drivers
  3. 2.3 Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Industry Opportunities and Challenges
  4. 2.4 Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Industry Restraints
3 Competitive Landscape by Company
  1. 3.1 Global Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Revenue by Company (2021-2026)
  2. 3.2 Global Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Players Revenue Ranking, 2024 VS 2025 VS 2026
  3. 3.3 Global Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Key Company Head office and Area Served
  4. 3.4 Global Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Company, Product Type & Application
  5. 3.5 Global Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Company Establishment Date
  6. 3.6 Market Competitive Analysis
  7. 3.6.1 Global Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Market CR5 and HHI
  8. 3.6.2 Global Top 5 and 10 Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Players Market Share by Revenue in 2025
  9. 3.6.3 2025 Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Tier 1, Tier 2, and Tier 3
4 Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Market by Type
  1. 4.1 Global Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Market Size by Type (2021 VS 2025 VS 2032)
  2. 4.2 Global Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Market Size by Type (2021-2032)
  3. 4.3 Global Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Market Size Share by Type (2021-2032)
5 Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Market by Application
  1. 5.1 Global Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Market Size by Application (2021 VS 2025 VS 2032)
  2. 5.2 Global Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Market Size by Application (2021-2032)
  3. 5.3 Global Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Market Size Share by Application (2021-2032)
6 Company Profiles
  1. 6.1 Novartis AG
  2. 6.1.1 Novartis AG Company Information
  3. 6.1.2 Novartis AG Business Overview
  4. 6.1.3 Novartis AG Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Revenue and Gross Margin (US$ Million) & (2021-2026)
  5. 6.1.4 Novartis AG Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Product Portfolio
  6. 6.1.5 Novartis AG Recent Developments
  7. 6.2 Pfizer Inc
  8. 6.2.1 Pfizer Inc Company Information
  9. 6.2.2 Pfizer Inc Business Overview
  10. 6.2.3 Pfizer Inc Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Revenue and Gross Margin (US$ Million) & (2021-2026)
  11. 6.2.4 Pfizer Inc Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Product Portfolio
  12. 6.2.5 Pfizer Inc Recent Developments
  13. 6.3 AstraZeneca Plc
  14. 6.3.1 AstraZeneca Plc Company Information
  15. 6.3.2 AstraZeneca Plc Business Overview
  16. 6.3.3 AstraZeneca Plc Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Revenue and Gross Margin (US$ Million) & (2021-2026)
  17. 6.3.4 AstraZeneca Plc Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Product Portfolio
  18. 6.3.5 AstraZeneca Plc Recent Developments
  19. 6.4 Seattle Genetics Inc
  20. 6.4.1 Seattle Genetics Inc Company Information
  21. 6.4.2 Seattle Genetics Inc Business Overview
  22. 6.4.3 Seattle Genetics Inc Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Revenue and Gross Margin (US$ Million) & (2021-2026)
  23. 6.4.4 Seattle Genetics Inc Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Product Portfolio
  24. 6.4.5 Seattle Genetics Inc Recent Developments
  25. 6.5 NuvOx Pharma LLC
  26. 6.5.1 NuvOx Pharma LLC Company Information
  27. 6.5.2 NuvOx Pharma LLC Business Overview
  28. 6.5.3 NuvOx Pharma LLC Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Revenue and Gross Margin (US$ Million) & (2021-2026)
  29. 6.5.4 NuvOx Pharma LLC Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Product Portfolio
  30. 6.5.5 NuvOx Pharma LLC Recent Developments
  31. 6.6 Modus Therapeutics Holding AB
  32. 6.6.1 Modus Therapeutics Holding AB Company Information
  33. 6.6.2 Modus Therapeutics Holding AB Business Overview
  34. 6.6.3 Modus Therapeutics Holding AB Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Revenue and Gross Margin (US$ Million) & (2021-2026)
  35. 6.6.4 Modus Therapeutics Holding AB Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Product Portfolio
  36. 6.6.5 Modus Therapeutics Holding AB Recent Developments
  37. 6.7 Gilead Sciences Inc
  38. 6.7.1 Gilead Sciences Inc Company Information
  39. 6.7.2 Gilead Sciences Inc Business Overview
  40. 6.7.3 Gilead Sciences Inc Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Revenue and Gross Margin (US$ Million) & (2021-2026)
  41. 6.7.4 Gilead Sciences Inc Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Product Portfolio
  42. 6.7.5 Gilead Sciences Inc Recent Developments
  43. 6.8 Bristol-Myers Squibb Company
  44. 6.8.1 Bristol-Myers Squibb Company Company Information
  45. 6.8.2 Bristol-Myers Squibb Company Business Overview
  46. 6.8.3 Bristol-Myers Squibb Company Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Revenue and Gross Margin (US$ Million) & (2021-2026)
  47. 6.8.4 Bristol-Myers Squibb Company Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Product Portfolio
  48. 6.8.5 Bristol-Myers Squibb Company Recent Developments
7 North America
  1. 7.1 North America Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Market Size (2021-2032)
  2. 7.2 North America Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Market Size by Type
  3. 7.2.1 North America Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Market Size by Type (2021-2026)
  4. 7.2.2 North America Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Market Size by Type (2027-2032)
  5. 7.2.3 North America Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Market Share by Type (2021-2032)
  6. 7.3 North America Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Market Size by Application
  7. 7.3.1 North America Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Market Size by Application (2021-2026)
  8. 7.3.2 North America Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Market Size by Application (2027-2032)
  9. 7.3.3 North America Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Market Share by Application (2021-2032)
  10. 7.4 North America Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Market Size by Country
  11. 7.4.1 North America Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Market Size by Country (2021 VS 2025 VS 2032)
  12. 7.4.2 North America Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Market Size by Country (2021-2026)
  13. 7.4.3 North America Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Market Size by Country (2027-2032)
  14. 7.4.4 North America Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Market Share by Country (2021-2032)
  15. 7.4.5 United States
  16. 7.4.6 Canada
  17. 7.4.7 Mexico
8 Europe
  1. 8.1 Europe Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Market Size (2021-2032)
  2. 8.2 Europe Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Market Size by Type
  3. 8.2.1 Europe Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Market Size by Type (2021-2026)
  4. 8.2.2 Europe Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Market Size by Type (2027-2032)
  5. 8.2.3 Europe Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Market Share by Type (2021-2032)
  6. 8.3 Europe Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Market Size by Application
  7. 8.3.1 Europe Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Market Size by Application (2021-2026)
  8. 8.3.2 Europe Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Market Size by Application (2027-2032)
  9. 8.3.3 Europe Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Market Share by Application (2021-2032)
  10. 8.4 Europe Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Market Size by Country
  11. 8.4.1 Europe Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Market Size by Country (2021 VS 2025 VS 2032)
  12. 8.4.2 Europe Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Market Size by Country (2021-2026)
  13. 8.4.3 Europe Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Market Size by Country (2027-2032)
  14. 8.4.4 Europe Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Market Share by Country (2021-2032)
  15. 8.4.5 Germany
  16. 8.4.6 France
  17. 8.4.7 U.K.
  18. 8.4.8 Italy
  19. 8.4.9 Russia
  20. 8.4.10 Nordic Countries
9 China
  1. 9.1 China Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Market Size (2021-2032)
  2. 9.2 China Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Market Size by Type
  3. 9.2.1 China Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Market Size by Type (2021-2026)
  4. 9.2.2 China Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Market Size by Type (2027-2032)
  5. 9.2.3 China Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Market Share by Type (2021-2032)
  6. 9.3 China Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Market Size by Application
  7. 9.3.1 China Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Market Size by Application (2021-2026)
  8. 9.3.2 China Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Market Size by Application (2027-2032)
  9. 9.3.3 China Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Market Share by Application (2021-2032)
10 Asia (Excluding China)
  1. 10.1 Asia Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Market Size (2021-2032)
  2. 10.2 Asia Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Market Size by Type
  3. 10.2.1 Asia Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Market Size by Type (2021-2026)
  4. 10.2.2 Asia Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Market Size by Type (2027-2032)
  5. 10.2.3 Asia Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Market Share by Type (2021-2032)
  6. 10.3 Asia Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Market Size by Application
  7. 10.3.1 Asia Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Market Size by Application (2021-2026)
  8. 10.3.2 Asia Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Market Size by Application (2027-2032)
  9. 10.3.3 Asia Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Market Share by Application (2021-2032)
  10. 10.4 Asia Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Market Size by Country
  11. 10.4.1 Asia Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Market Size by Country (2021 VS 2025 VS 2032)
  12. 10.4.2 Asia Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Market Size by Country (2021-2026)
  13. 10.4.3 Asia Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Market Size by Country (2027-2032)
  14. 10.4.4 Asia Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Market Share by Country (2021-2032)
  15. 10.4.5 Japan
  16. 10.4.6 South Korea
  17. 10.4.7 Taiwan
  18. 10.4.8 Southeast Asia
  19. 10.4.9 India
  20. 10.4.10 Australia
11 South America, Middle East & Africa
  1. 11.1 South America, Middle East & Africa Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Market Size (2021-2032)
  2. 11.2 South America, Middle East & Africa Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Market Size by Type
  3. 11.2.1 South America, Middle East & Africa Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Market Size by Type (2021-2026)
  4. 11.2.2 South America, Middle East & Africa Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Market Size by Type (2027-2032)
  5. 11.2.3 South America, Middle East & Africa Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Market Share by Type (2021-2032)
  6. 11.3 South America, Middle East & Africa Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Market Size by Application
  7. 11.3.1 South America, Middle East & Africa Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Market Size by Application (2021-2026)
  8. 11.3.2 South America, Middle East & Africa Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Market Size by Application (2027-2032)
  9. 11.3.3 South America, Middle East & Africa Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Market Share by Application (2021-2032)
  10. 11.4 South America, Middle East & Africa Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Market Size by Country
  11. 11.4.1 South America, Middle East & Africa Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Market Size by Country (2021 VS 2025 VS 2032)
  12. 11.4.2 South America, Middle East & Africa Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Market Size by Country (2021-2026)
  13. 11.4.3 South America, Middle East & Africa Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Market Size by Country (2027-2032)
  14. 11.4.4 South America, Middle East & Africa Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Market Share by Country (2021-2032)
  15. 11.4.5 Brazil
  16. 11.4.6 South Africa
  17. 11.4.7 Saudi Arabia
  18. 11.4.8 Turkey
  19. 11.4.9 Argentina
  20. 11.4.9 UAE
  21. 11.4.9 Egypt
  22. 11.4.9 Chile
12 Concluding Insights
    13 Appendix
    1. 13.1 Reasons for Doing This Study
    2. 13.2 Research Methodology
    3. 13.3 Research Process
    4. 13.4 Authors List of This Report
    5. 13.5 Data Source
    6. 13.5.1 Secondary Sources
    7. 13.5.2 Primary Sources
    8. 13.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research, Inc.
    Talk to an analyst